













doi:10.101Incidence and Risk Factors for Early Hepatotoxicity
and Its Impact on Survival in Patients with
Myelofibrosis Undergoing Allogeneic Hematopoietic
Cell Transplantation
Kit Man Wong,1 Eshetu G. Atenafu,2 Dennis Kim,3 John Kuruvilla,3
Jeffrey H. Lipton,3 Hans Messner,3 Vikas Gupta1,3Allogeneic hematopoietic cell transplantation (HCT) is commonly associated with hepatic complications.
Patients with myelofibrosis (MF) often develop liver dysfunction in the early posttransplantation period; how-
ever, this has not yet been studied in a systematic fashion. We retrospectively evaluated 53 patients with MF
who underwent HCT to assess the prevalence of acute liver toxicity and risk factors and the impact on sur-
vival.We compared the prevalence of acute hepatic complications in that group and a matched control group
of 53 patients with myelodysplastic syndrome (MDS). In the MF group, during the first 6 weeks after HCT, the
incidence of mild (34.2-102.6 mM), moderate (102.6-342 mM), and severe (.342 mM) hyperbilirubinemia was
34%, 40%, and 4%, respectively (normal,\22 mM). The incidence of mild/moderate transaminitis (2-10 times
the upper limit of normal) was 23%, and that of severe transaminitis (.10 times the upper limit of normal)
was 6%. Veno-occlusive disease as defined by the Baltimore criteria was observed in 19 patients (36%) in the
MF group. Compared with MDS, MF was associated with a significantly higher incidence of moderate/severe
hyperbilirubinemia (44% versus 21%; P 5 .02) and veno-occlusive disease (36% versus 19%; P 5 .05).
A history of portal hypertension, biopsy-proven hepatic iron overload, or splanchnic vein thrombosis was
a strong predictor of moderate/severe hyperbilirubinemia (P 5 .02). Acute hepatocellular injury
with moderate/severe hyperbilirubinemia or transaminitis was associated with inferior survival at 12 months
(P 5 .02) in the MF group. We conclude that patients with MF are at significant risk of early hepatotoxicity
after HCT, which is associated with an adverse impact on survival.
Biol Blood Marrow Transplant 18: 1589-1599 (2012)  2012 American Society for Blood and Marrow TransplantationKEY WORDS: Myelofibrosis, Allogeneic, Transplantation, Liver toxicity, Regimen-relatedINTRODUCTION
Allogeneic hematopoietic cell transplantation
(HCT) is the only curative treatment for myelofibrosis
(MF) [1]. Hepatotoxicity is a known complication of
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6/j.bbmt.2012.04.011ity [2-4]. Mild elevations in liver enzymes commonly
occur after HCT [4,5]. Severe acute hepatocellular
injury with aspartate aminotransferase (AST) level
.1500 U/L, although less frequent (1.4%), has been
reported with poor outcomes [2]. Previous studies
have shown that the most common etiologies of
abnormal liver function tests after HCT are hepatic
graft-versus-host disease (GVHD), drug-induced
hepatitis, and iron overload [5], whereas severe hepato-
toxicity (AST .1500 U/L) is mediated mainly by
veno-occlusive disease (VOD) and hypoxia [2].
It has been our clinical observations that patients
with MF undergoing HCT have a high risk of hepa-
totoxicity. Moreover, they often have no apparent or
known risk factors for post-HCT hepatic injury and
tend to have poor outcomes. MF is a myeloprolifera-
tive disorder with several features that may impair
liver function and predispose to hepatocellular injury,
including hepatic extramedullary hematopoiesis and
iron overload from repeated blood transfusions. In1589
1590 Biol Blood Marrow Transplant 18:1589-1599, 2012K. M. Wong et al.addition, patients with MF are at risk for splanchnic
vein thrombosis (SVT), leading to portal hyperten-
sion (PHT) [6,7]. Some patients develop overt
manifestations of PHT, including ascites requiring
diuretics and/or therapeutic paracentesis, as well as
esophageal varices necessitating endoscopic
intervention. However, it is possible that others
might have asymptomatic PHT that was undetected
before HCT. The available data on PHT in MF
are anecdotal, and the exact incidence is not clear
[8]. To systematically investigate and characterize
the acute hepatocellular injury occurring in MF pa-
tients after HCT, we conducted a retrospective
case-control analysis on the incidence of liver
toxicity, risk factors, and its impact on survival.PATIENTS AND METHODS
Patients
We studied 53 consecutive adult patients who
underwent HCT forMF between April 1981 and April
2011 at PrincessMargaretHospital (UniversityHealth
Network), Toronto, Ontario, Canada. The study pop-
ulation was obtained from a prospective database of
HCT patients at our center. The majority (94%) of
the HCTs were performed after 1995. MF was
diagnosed based on established criteria [9,10] and
included primary MF, postpolycythemia rubra vera
MF (PPV-MF), and postessential thrombocytopenia
MF (PET-MF).
A matched cohort of 53 patients with myelodys-
plastic syndrome (MDS) from the HCT database
served as the control group. Selection criteria for the
control population were donor type (related versus un-
related), conditioning intensity (full versus reduced),
year of HCT 6 3 years, and age at HCT 6 5 years.
All 53 patients were matched for donor type and
conditioning intensity. Thirty-three patients (62%)
met all 4 criteria, 18 (34%) met 3 criteria, and 2 (4%)
met 2 criteria. The study was approved by the Cancer
Registry Data Access Committee and the University
Health Network’s Research Ethics Board (study no.
10-0478-CE).Conditioning Regimen and GVHD Prophylaxis
Patients were treated with conditioning regimens
according to institutional protocols in place at the
time of HCT. Conditioning intensity was defined as
full or reduced according to the Center for Interna-
tional Blood andMarrow Transplant Research criteria
[11]. The decision to offer full-intensity or reduced-
intensity conditioning was based on patient age and
comorbidities, as described previously [12].
GVHD prophylaxis consisted of a calcineurin
inhibitor (cyclosporine or tacrolimus) with methotrex-ate or a calcineurin inhibitor with mycophenolate.
Eight of 16 patients (50%) who underwent matched
unrelated HCT received serotherapy with alemtuzu-
mab or thymyglobulin for additional GVHD
prophylaxis.Variables and Definitions
Patient demographic data, information onMF and
liver disease characteristics, details of HCT and
pretransplantation and posttransplantation liver func-
tion, and data on survival endpoints were collected
from the HCT database and patient records. Hepato-
megaly was arbitrarily defined as mild/moderate if the
liver measured 15.5-18.5 cm on radiographic imaging
or was palpable up to 5 cm below the costal margin,
and as severe if the liver was .18.5 cm on imaging
or palpable .5 cm below the costal margin. Spleno-
megaly was arbitrarily defined as mild/moderate if
the spleen measured.12 cm on imaging or was palpa-
ble up to 10 cm below the costal margin, and as severe
if it was.20 cm on imaging or palpable.10 cm below
the costal margin. Transfusion dependency was
defined as receipt of at least 2 units of packed red blood
cells every 4 weeks for 3 months before HCT in the
absence of bleeding, as described recently [13].
Disease risk in MF patients was stratified by the
Dynamic International Prognostic Scoring System,
which comprises 5 risk factors: age .65 years, hemo-
globin\100 g/L, history of leukocyte count .25 
109/L, peripheral blood blasts$1%, and the presence
of constitutional symptoms. Risk categories based on
this scoring system were defined as low (score 0), inter-
mediate 1 (score 1-2), intermediate 2 (score 3-4), and
high (score 5-6) [14]. In the MDS population, the
International Prognostic Scoring System was used
for risk stratification, which includes the variables
bone marrow blast percentage (\5%, 5%-10%,
11%-20%, or 21%-30%), karyotype (normal, Y, 5q,
20q, other abnormalities; complex or chromosome 7
abnormalities), and cytopenias (0 or 1; 2 or 3).
The scoring system defining the low-risk, intermediate
1-risk, intermediate 2-risk, and high-risk groups has
been described previously [15].
The Pretransplant Assessment of Mortality (PAM)
score is a prognostic scoring system developed and val-
idated to predict the risk of mortality at 2 years after
HCT in various hematologic malignancies (http://
cdsweb.fhcrc.org/pam/pam.aspx) [16]. We evaluated
whether the PAM score was associated with acute
hepatic dysfunction. All of the patients in the MDS
control group were classified with high-risk disease,
because they either had relapsed or had not achieved
remission. Although MF was not included in the scor-
ing algorithm, the patients in the MF group were
assigned a high-risk disease category similar to the
risk of nonremitting MDS.
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was defined by any history of SVT, known PHT or its
manifestations (eg, ascites, esophageal varices), and ev-
idence of cirrhosis or hepatic iron overload on biopsy.
Liver function was evaluated by AST and total serum
bilirubin levels measured on or before the day of ad-
mission (preconditioning), on the day of stem cell infu-
sion (day 0), and at peak levels within the first 6 weeks
after HCT. AST elevation (upper limit of normal
[ULN], 34 U/L) was graded based on Bearman toxic-
ity criteria as mild (2-5 times ULN), moderate (5-10
times ULN), or severe (.10 times ULN) [17]. Hyper-
bilirubinemia (normal,\22 mM) also was categorized
as mild (34.2-102.6 mM), moderate (102.6-342 mM), or
severe (.342 mM). In addition, albumin level was eval-
uated at preconditioning, on day 0, and at its nadir
within the first 6 weeks after HCT.
The occurrence of VOD during the first 6 weeks
after HCT was identified from patient records. The
diagnosis of VOD was made in the setting of hyperbi-
lirubinemia ($34.2 mM)with at least 2 of the following
clinical signs: ascites, hepatomegaly, or weight
gain .5% above baseline based on the Baltimore cri-
teria [18]. VODwas classified as severe in the presence
of pulmonary dysfunction (ie,\90% oxygen satura-
tion on room air or a requirement for oxygen supple-
mentation or ventilation due to fluid overload) and/
or renal impairment (ie, creatinine $3 times the base-
line value, glomerular filtration rate#40%, or need for
dialysis) [19]. Patients with VOD were treated with
supportive therapy.
Study endpoints of interest were overall survival
(OS) and nonrelapse mortality (NRM). In addition,
the duration required for engraftment of neutrophils
(ie, first of 3 consecutive days with a neutrophil
count $0.5  109/L without granulocyte colony-
stimulating factor support) and platelets (ie, first of 7
consecutive days with a platelet count $20  109/L
without transfusions) was determined.Statistical Analysis
Descriptive statistics were used to assess patient
demographic data, disease characteristics, and related
covariates of interest. Categorical variables are
expressed as count and proportions, and continuous
variables are expressed as median and range. Changes
in AST, bilirubin, and albumin from baseline levels
were quantified. Associations between risk variables
and abnormal liver function tests were investigated
using the Fisher exact test for categorical variables
and Wilcoxon rank sum test for continuous variables.
The MF and MDS groups were compared in terms
of baseline characteristics and incidence of hepatotox-
icity using the Student t test for continuous variables
and the c2 or Fisher exact test for categorical
variables. OS was analyzed using the Kaplan-Meiermethod, where the time to event was in months from
day 0 to death or last follow-up. The impact of
transaminitis and hyperbilirubinemia on OS was eval-
uated using the Wilcoxon c2 test. The cumulative
incidence of NRM was calculated by taking the
competing risk of relapse into account. Associations
of AST and bilirubin levels with engraftment times
were evaluated by analysis of variance. A P value
of #.05 was considered significant. All statistical
analyses were performed using SAS version 9.2 (SAS
Institute, Cary, NC).RESULTS
Characteristics of the Study and Control
Populations
The 53 patients in the MF group included 39 with
primary MF, 4 with PPV-MF, and 10 with PET-MF.
The majority (94%) of HCTs were performed after
1995. Characteristics of the MF and MDS control
groups are summarized in Table 1. Compared with the
case-matched MDS group, the MF group had a signifi-
cantly higher proportion of males and, as expected,
higher rates of hepatomegaly, splenomegaly, and history
of significant liver disease or SVT.Baseline AST and bil-
irubin levels were similar in the 2 groups, whereas albu-
min level was slightly higher in the MDS group.
In the MF group, the median duration of disease
from diagnosis to HCT was 15 months (range, 2.4
months to 24.4 years). Of the 46 patients who never
underwent splenectomy, splenomegaly was evident in
39 (85%), with severe splenic enlargement seen in 21
(46%). Hepatomegaly was detected in 28 patients
(53%). The MF group had a high rate of transfusion
dependency (60%), which was associated with elevated
baseline ferritin concentration (mean, 1707 mg/L;
normal, 4.6-204 mg/L). One patient was positive for
hepatitis B surface antigen, and all patients were nega-
tive for hepatitis C antibody. Eleven patients (21%)
had evident hepatic disease and/or SVT, including
chronic portal or splenic vein thrombosis (n 5 4),
ascites (n 5 3), and biopsy-proven hepatic iron over-
load (n 5 4). Hemosiderosis was graded as 3-4 (out
of 4) in all cases of liver biopsy.Incidence of Acute Hepatocellular Injury
Liver dysfunction, as defined by transaminitis and/
or abnormal bilirubin, occurred in 79% of the MF
group posttransplantation. In the MF group, a signifi-
cant rise from preconditioning to peak levels within
the first 6 weeks was observed for AST (median, 20-
47 U/L; P \ .0001) (Figure 1A). The frequency of
transaminitis (AST .2 times the ULN) was 29%,
with 6% of cases involving significant AST elevation
(.10 times the ULN) (Figure 2A). Bilirubin level
Table 1. Patient, Disease, and Transplant-Related Characteristics of the Study and Control Populations
MF (n 5 53) Control (n 5 53) P Value
Sex, n (%)
Male 38 (72) 26 (49) .02
Female 15 (28) 27 (51)
Age at HCT, years, median (range) 50 (29-69) 51 (27-66) .69
Diagnosis, n (%)
Primary 39 (74) 40 (75) .82
Secondary 14 (26) 13 (25)
PPV-MF 4 (8) —
PET-MF 10 (19) —
Duration of MF from diagnosis to HCT, months, median (range) 15 (2-297) 14 (1-154) .13
Pre-HCT JAK2 mutation status, n (%)
Positive 12 (23) —
Negative 4 (8) —
Missing 37 (70) —
Prognostic category, n (%) DIPSS IPSS
Low risk 0 (0) 0 (0)
Intermediate-1 risk 6 (11) 3 (6)
Intermediate-2 risk 18 (34) 14 (26)
High risk 29 (55) 27 (51)
Missing 0 (0) 9 (17)
Transfusion dependency, n (%) 32 (60) 31 (62) .87
Pre-HCT ferritin level (mg/L, mean ± SD) 1707 ± 1928 1810 ± 1678 .82
ECOG performance status at HCT, n (%)
0 15 (28) 17 (35) .50
1 32 (60) 24 (49)
$2 6 (11) 8 (16)
Hepatomegaly, n (%)
Normal size 25 (47) 45 (90) <.0001
Mild to moderately enlarged 13 (25) 4 (8)
Severely enlarged 15 (28) 1 (2)
Spleen status at HCT, n (%)
Splenectomy 7 (13) 1 (2) <.0001
Normal size 7 (13) 36 (72)
Mild to moderately enlarged 18 (34) 11 (22)
Severely enlarged 21 (40) 2 (4)
CMV status of recipient, n (%)
Positive 25 (47) 28 (53) .69
Negative 26 (49) 24 (45)
Missing 2 (4) 1 (2)
History of significant liver disease or SVT, n
Thrombosis 4 1 .02
Ascites 3 0
Esophageal varices 0 0
Hepatic iron overload 4 2
Baseline liver function tests, median (range)
AST, U/L 20 (8-90) 22 (8-76) .60
Total bilirubin, mM 12 (4-38) 11 (5-34) .24
Albumin, g/L 39 (30-49) 41 (32-49) .0001
Donor type, n (%)
Related 37 (70) 37 (70) 1.00
Unrelated 16 (30) 16 (30)
Conditioning regimen, n (%)
Myeloablative 35 (66) 35 (66)
CY + TBI 1200 cGy 32 24
Bu (oral) + CY 3 9
Flu + Bu (i.v. 12.8 mg/kg) + TBI 400 cGy 0 2
Reduced intensity 18 (34) 18 (34)
Flu + TBI 200 cGy 3 3
Flu + Bu (i.v. 6.4 mg/kg) 9 15
Flu + Bu (i.v. 6.4 mg/kg) + TBI 200 cGy 2 0 1.00
Flu + melphalan 4 0 1.00
PAM disease category, n (%)
1 (score 9-16) 0 (0) 0 (0) .003
2 (score 17-23) 22 (42) 10 (19)
3 (score 24-30) 18 (34) 35 (66)
4 (score 31-44) 9 (17) 4 (8)
Missing 4 (8) 4 (8)
DIPSS indicates Dynamic International Prognostic Scoring System; IPSS, International Prognostic Scoring System; ECOG, Eastern CooperativeOncology
Group; CMV, cytomegalovirus; CY, cyclophosphamide; TBI, total body irradiation; Bu, busulfan; Flu, fludarabine.
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Figure 1. Levels of AST (A), bilirubin (B), and albumin (C) at preconditioning, on the day of stem cell infusion, and at peak (or nadir for albumin) within
the first 6 weeks after HCT.
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(Figure 1B). The incidence of mild (34.2-102.6 mM),
moderate (102.6-342 mM), and severe (.342 mM)
hyperbilirubinemia was 34%, 40%, and 4%, respec-
tively (Figure 2B). There were no significant differ-
ences in AST and bilirubin levels between baseline
and the day of stem cell infusion (ie, after receipt of
the conditioning regimen); however, albumin level
decreased from baseline to its nadir (median, 39-29g/L; P\ .0001) (Figure 1C). A reduction of $10
g/L was observed in 23 patients (44%).
The MDS control group also exhibited significant
changes in AST (median, 22-62 U/L; P 5 .0005) and
bilirubin (median, 11-51 U/L; P \ .0001), as well
as reduced albumin levels (median, 41-31 U/L; P\
.0001) (Figure 1D-F). However, the frequency of
moderate/severe hyperbilirubinemia was significantly
lower than that in the MF group (44% versus 21%;
Figure 2. Peak AST, bilirubin, and VOD in the MF group (A-C) and the MDS control group (D-F).
1594 Biol Blood Marrow Transplant 18:1589-1599, 2012K. M. Wong et al.P5 .02). No difference in AST was observed between
the 2 groups (Figure 2).
Incidence of VOD
VOD as defined by the Baltimore criteria [18] was
observed in 19 patients (36%) in the MF group and 10
patients (19%) in the MDS group (P 5 .05)
(Figure 2C and F). Eight of the 19 patients in the
MF group (42%) and 4 of 10 in the MDS (40%) had
severe VOD due to renal and/or pulmonary failure.
The cumulative incidence of severe VOD in the total
MF population was 15%. The outcome of severe
VOD was uniformly fatal irrespective of the diagnosis.Risk Factors for Hepatotoxicity in MF
Potential factors that predispose to hepatic injury
in patients withMFwere assessed for significant corre-
lation with peak AST and bilirubin levels in the first 6
weeks after HCT (Table 2). Our analysis demon-
strated that older age at HCT, female sex, and longer
disease duration were significantly associated with
AST elevation. A significant history of liver disease
or SVT was strongly associated with hyperbilirubine-
mia (P5 .02). In contrast, no known variable appeared
to influence the changes in albumin levels.
Dynamic International Prognostic Scoring System
score, etiology of MF (ie, primary, PPV, or PET),
Table 2. Univariate Analysis of Liver Function Test Results in Patients with MF
Variable
AST* Bilirubin† Albumin Reduction‡
Median P Value Median P Value Median P Value
Age (continuous variable) — .006 — .17 — .41
Sex
Male 46 .0006 86 .77 9 .89
Female 90 96 9
History of significant liver disease or SVT
Present 43 .37 188 .02 8 .51
Absent 49 69 9
Specific diagnosis
Primary 46 .39 89 .79 9 .81
PPV or PET 51 87 9
Disease duration — .009 — .54 — .99
DIPSS classification
Intermediate 1 risk 108 .25 104 .38 10 .99
Intermediate 2 risk 45 79 9
High risk 47 82 9
Transfusion dependency
Yes 46 .97 95 .54 9 .64
No 47 82 9
Ferritin (continuous variable) — .64 — .29 — .16
Splenomegaly
Splenectomy 61 .27 105 .14 11 .81
Normal or mild 47 78 9
Severe 47 115 9
Hepatomegaly
Normal 48 .30 82 .62 8 .08
Mild or moderate 50 78 10
Severe 47 115 11
ECOG performance status
0 47 .89 79 .27 18 .71
$1 47 104 16
Donor match
Related 49 .29 89 .66 18 .36
Unrelated 47 92 16
Conditioning intensity
Full 47 .17 105 .09 18 .46
Reduced 46 56 16
PAM disease category
2 (score 17-23) 50 .92 62 .15 9 .07
3 (score 24-30) 51 58 10
4 (score 31-44) 60 168 8
DIPSS indicates Dynamic International Prognostic Scoring System; ECOG, Eastern Cooperative Oncology Group.
*Peak AST in the first 6 weeks after HCTanalyzed as a continuous variable.
†Peak bilirubin in the first 6 weeks after HCTanalyzed as a categorical variable (ie, normal, mild, moderate/severe).
‡Decrease in albumin level from baseline to nadir in the first 6 weeks after HCTanalyzed as a continuous variable.
Biol Blood Marrow Transplant 18:1589-1599, 2012 1595Acute Hepatotoxicity after HCT in Myelofibrosistransfusion dependency, pretransplantation ferritin
level, degree of hepatosplenomegaly, Eastern Cooper-
ative Oncology Group status, donor match (related
versus unrelated), and PAM risk category had no im-
pact on liver function. The use of full-intensity condi-
tioning was associated with a greater tendency toward
severe hyperbilirubinemia compared with reduced-
intensity conditioning, although the difference was
not statistically significant (P 5 .09).
Impact of Hepatocellular Injury on Hematologic
Recovery in MF
In theMF group, neutrophil engraftment occurred
in 47 patients (89%) and platelet engraftment occurred
in 41 (77%). Engraftment was attained at a median of
22 days (range, 13-47 days) for neutrophils and 25 days
(range, 13-183 days) for platelets. The presence of hy-perbilirubinemia and transaminitis, even if severe, did
not prolong the time to hematologic recovery of neu-
trophils or platelets. The median time to platelet en-
graftment was 23 days, 23 days, and 28 days in
normal, mild, and moderate/severe hyperbilirubine-
mia, respectively (P 5 .14).
Impact of Hepatocellular Injury on Survival in
MF
We investigated the effects of liver dysfunction on
survival in the patients withMF (Table 3). The median
survival in the MF group overall was 18.6 months, in-
cluding 12 months in patients with mild hyperilirubi-
nemia and 6.4 months in those with moderate/severe
hyperbilirubinemia (P 5 .02). Similarly, the median
survival for patients with mild and severe transaminitis
was 10.2 and 3 months, respectively (P 5 .02).
Table 3. Impact of Hepatotoxicity on Survival Outcomes
Outcome
Transaminitis (AST Level)* Hyperbilirubinemia*
Mild (2-5 Times ULN)
Moderate/Severe
(>5 Times ULN) P Value Mild (34.2-102.6 mM)
Moderate/Severe
(>102.6 mM) P Value
Median survival, months 10.2 3.0 .02† 12.0 6.4 .02†
Hazard ratio for NRM‡ 1.247 — .70 2.154 — .34
— 7.235 .005 — 4.36 .05
*Peak AST and bilirubin in the first 6 weeks after HCT (AST ULN, 34 U/L; normal bilirubin, <22 mM).
†P values obtained from the Wilcoxon test of equality over strata.
‡Hazard ratios for NRM relative to AST <2 times ULN and bilirubin <34.2 mM, respectively.
1596 Biol Blood Marrow Transplant 18:1589-1599, 2012K. M. Wong et al.Survival at 12 months was assessed by the Kaplan-
Meier method. Eight patients (15%) experienced dis-
ease relapse. The impact of hyperbilirubinemia and
transaminitis on NRM was evaluated. Moderate/
severe hyperbilirubinemia predicted inferior OS (P 5Figure 3. Impact of hyperbilirubinemia during the first 6 weeks po.02) and showed a tendency toward increased NRM
(P5 .09) at 12 months after HCT (Figure 3). Patients
with transaminitis also had inferior OS (P 5 .02) and
NRM (P 5 .02). The hazard ratios for NRM in the
presence of moderate and/or severe increases inst-HCTon 12-month OS (A) and NRM (B) in the MF group.
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.005), respectively (Table 3).DISCUSSION
This is the first study to investigate acute hepato-
cellular injury after HCT specifically in patients with
MF, a group predisposed to underlying liver
dysfunction. Our results indicate a significant risk of
hepatotoxicity in this population in the first 6 weeks af-
ter HCT. In particular, a history of liver disease or
SVT was a strong predictor of hyperbilirubinemia.
Compared with the control group, the MF group
had a significantly higher incidence of moderate/se-
vere hyperbilirubinemia and VOD. Importantly, we
demonstrated that acute liver injury led to poorer OS
in patients with MF undergoing HCT.
Hepatotoxicity is a common complication of HCT
[4,5]. A prospective study of 115 patients who
underwent HCT for various myeloid malignancies at
our center found an 11% incidence rate of grade 2
hepatic toxicity according to the Bearman toxicity
criteria, and a 3% incidence rate of severe VOD as
defined by the Baltimore criteria (Vikas Gupta,
unpublished data). In comparison, 77% of the
patients in our MF group had hyperbilirubinemia
and 15% had severe VOD during the early
posttransplantation period. Thus, our findings
suggest a higher rate of significant liver injury in MF
compared with other indications for HCT, which
was further supported by the lower incidence of
moderate/severe hyperbilirubinemia in our control
group of case-matched patients with MDS (P 5 .02).
The association between MF and early post-HCT
liver dysfunction raises some important questions:
What are the additional factors predisposing MF
patients to hepatotoxicity? Can these potential mecha-
nisms be modified to reduce the risk of liver injury in
patientswithMFundergoingHCT?MF is amyelopro-
liferative disorder with several features that may affect
hepatic function and account for the increased risk of
liver injury afterHCT.PHTand its associatedmanifes-
tations (eg, ascites, varices) are nontrivial complications
of MF, with an incidence of 9%-18% [20]. It is likely
thatmany cases of PHT in patients withMF are asymp-
tomatic [8]. Splenomegalywas once thought to increase
hepatic blood flow and thus portal pressure, which de-
creases after splenectomy [20,21]. Other mechanisms
contributing to PHT have been proposed, including
portal and hepatic vein thrombosis [6,7] and hepatic
extramedullary hematopoiesis [8,22], and there is
increasing evidence for a role of sinusoidal fibrosis
[20,23-26]. A clinicopathological study of PHT
in myeloproliferative disorders based on autopsy
findings in patients with MF or PRV demonstrated
a strong correlation of variceal hemorrhage or asciteswith thrombosis in the portal veins, whereas ascites
was also associated with hepatic vein thrombosis [20].
In fact, MF is known to induce a prothrombotic state
[27,28], which may predispose to thrombotic lesions
in splanchnic veins, leading to PHT. Recently,
intrahepatic angiogenesis and sinusoidal remodeling
have emerged as novel mechanisms of sinusoidal
resistance and PHT, in which the sinusoidal
endothelial cells (SECs) and hepatic stellate cells
(HSCs) play key roles [29]. In particular, HSCs have
contractile properties and are activated by vasoactive
substances (eg, endothelin-1), changes in the extracellu-
lar matrix, and the presence of growth factors,
cytokines, oxidative stress, and SEC dysfunction
[29,30]. It is plausible that signaling molecules
secreted from hematopoietic cells involved in hepatic
extramedullary hematopoiesis in MF lead to abnormal
SEC function while stimulating the recruitment and
activity of HSCs.
In addition, hepatic iron overload can promote
liver injury. It is predictive of increased liver failure
and mortality in transfusion-dependent patients [31].
It is commonly seen in HCT recipients [32,33], and
there is evidence that it mediates hepatotoxicity after
HCT, especially in long-term follow-up [34,35].
Chelation therapy has been shown to reduce
mortality after HCT [32]. In the present study, using
a strict definition of transfusion dependency [13],
60% of the patients with MF were red cell
transfusion-dependent, reflecting the high-risk nature
of MF usually referred for HCT.
VOD is a common etiology of liver dysfunction in
the early post-HCT period [32]. Its incidence rate
varies among studies but is generally around 10% after
full-intensity conditioning [36]. The 36% incidence
rate of VOD in our MF group as defined by the
Baltimore criteria is significantly higher than that
seen in our MDS control group (P 5 .05), in the pub-
lished literature, and in patients with other myeloid
malignancies treated at our center [12].
Importantly, our data show a correlation between
the development and severity of hepatotoxicity and
significantly poorer OS at 12 months after HCT.
Indeed, our results confirm those fromprevious studies
that established the prognostic value of hyperbilirubi-
nemia, a key marker of liver dysfunction, in the post-
HCT setting [2,37,38]. Our findings have several
implications for patient management. They are useful
in patient counseling and improving the selection of
patients with MF for HCT. In addition, they raise
the question of whether all patients with MF who
are evaluated for HCT should be screened for
asymptomatic PHT with such investigations as upper
GI endoscopy and abdominal Doppler ultrasound.
The decision to offer HCT to patients with MF and
PHT who might be at greater risk for transplantation
complications should be weighed carefully against
1598 Biol Blood Marrow Transplant 18:1589-1599, 2012K. M. Wong et al.emerging experimental drug therapies. Furthermore,
such individuals undergoing HCT may benefit from
the use of reduced-intensity conditioning [38]. Other
measures, including chelation therapy for iron
overload [32] and defibrotide or ursodiol for VOD
prophylaxis [39,40], may be useful in some patients.
Based on the findings of the present study, our
program implemented screening for asymptomatic
PHT in the pretransplantation workup of patients
with MF. Since the implementation of this policy 6
months ago, we have screened 5 patients in the
pretransplantation setting and have identified 1 patient
with asymptomatic grade 3 varices and 1 patient with
portal vein thrombosis.
A major limitation of this study is its small sample
size. MF is a rare disease indication for HCT, and even
large transplant centers perform only a handful of
HCTs for MF each year. The retrospective nature of
this analysis also makes it difficult to address the etiol-
ogies of liver dysfunction. Nevertheless, this study
establishes that hepatotoxicity is a significant issue in
patients withMFundergoingHCTand suggests a pos-
sible role of screening for liver disease and/or PHT as
a potentially modifiable risk factor in this population.
A future prospective study is needed to confirm the
utility of screening for PHT as part of the pre-HCT
workup in patients with MF.ACKNOWLEDGMENTS
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